Vertrix Wealth Management LLC Invests $2.67 Million in Abbott Laboratories $ABT

Vertrix Wealth Management LLC purchased a new stake in shares of Abbott Laboratories (NYSE:ABT) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 29,377 shares of the healthcare product maker’s stock, valued at approximately $2,666,000.

Several other large investors also recently bought and sold shares of ABT. Brighton Jones LLC increased its position in Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after acquiring an additional 4,755 shares during the last quarter. Sivia Capital Partners LLC grew its stake in shares of Abbott Laboratories by 3.5% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after purchasing an additional 162 shares during the period. United Bank increased its position in shares of Abbott Laboratories by 7.4% during the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after purchasing an additional 2,001 shares during the last quarter. Main Street Financial Solutions LLC lifted its stake in shares of Abbott Laboratories by 13.6% in the 2nd quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock worth $1,618,000 after purchasing an additional 1,428 shares during the period. Finally, Canada Pension Plan Investment Board grew its position in Abbott Laboratories by 25.6% during the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock valued at $195,267,000 after buying an additional 292,547 shares during the period. 75.18% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on ABT shares. Benchmark cut their price objective on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Weiss Ratings upgraded Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday. The Goldman Sachs Group reduced their price target on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research report on Wednesday, May 27th. Piper Sandler reiterated an “overweight” rating and set a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Finally, BTIG Research raised their target price on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus price target of $118.17.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $107.81 on Monday. The stock has a 50-day moving average price of $95.51 and a 200 day moving average price of $99.87. The stock has a market capitalization of $186.56 billion, a P/E ratio of 34.89, a P/E/G ratio of 2.09 and a beta of 0.59. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same period in the prior year, the company posted $1.26 EPS. The firm’s revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be given a dividend of $0.63 per share. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio is currently 81.55%.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Diagnostics expansion strengthens growth outlook: Abbott is broadening its Diagnostics growth base through its Exact Sciences relationship and oncology testing expansion. Gains in cancer diagnostics and resilient routine testing are helping offset weaker respiratory-related demand, potentially making growth less dependent on COVID and respiratory testing. Here’s How ABT Broadens Diagnostics Growth Base With Oncology Expansion
• Positive Sentiment: Analysts remain bullish: Although ABT has lagged the broader market over the past year, Wall Street analysts continue to view the stock favorably and see further upside potential based on Abbott’s diversified healthcare portfolio and earnings durability. Abbott Stock: Is Wall Street Bullish or Bearish?
• Positive Sentiment: Reliable-growth investment case: An investor letter from Matrix Asset Advisors presents Abbott as a compelling long-term healthcare holding, emphasizing its dependable growth profile and diversified end markets. Broader nutritional-market growth could also support Abbott’s nutrition business over time. What Makes Abbott Laboratories a Compelling Investment Opportunity Global Nutritional Market Outlook
• Neutral Sentiment: Value debate remains: Comparisons with Envista (NVST) focus on which medical-products stock offers better value. The coverage may prompt investors to weigh Abbott’s premium valuation against its stronger diversification and consistency, but it does not represent a new company-specific catalyst. NVST vs. ABT: Which Stock Is the Better Value Option?
• Neutral Sentiment: Competitive backdrop: Analysts’ discussion of Abbott alongside other healthcare companies provides sector context, but no major change to Abbott’s outlook is indicated. Boston Scientific’s reduced 2026 guidance could be relatively favorable for Abbott if investors rotate toward companies with steadier execution, though it also underscores competitive pressures in medical devices. Analysts Offer Insights on Healthcare Companies

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.